Lycia Therapeutics, Inc. (LYCA)
Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.
Industry: Biotechnology
Lycia Therapeutics Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 52.09M shares outstanding
USLycia Therapeutics, Inc. operates as a clinical-stage biotechnology company.
It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases.
The company was founded in 2019 and is headquartered in South San Francisco, CA.
Leadership
Aetna Wun Trombley
CEO, Secretary, President & Director
Steve Staben
Chief Scientific Officer
Amy Bachrodt
Chief Financial Officer
Carolyn R. Bertozzi
Founder & Chair of Scientific Advisory Board
Employees
--
Country
US
Sector
Healthcare
Website
lyciatx.com
| Name | Shares | % | Source |
|---|---|---|---|
 ELI LILLY & Co 10% Owner | 1.1M | 2.1% | FORM 4 |
 Bertozzi Carolyn R 10% Owner | 904.8K | 1.7% | FORM 4 |
 Staben Steven Chief Scientific Officer, 10% Owner | 55.4K | 0.1% | FORM 4 |
 Fischer Laurent Director | 33.3K | 0.1% | FORM 4 |
Insiders
- ELI LILLY & Co10% Owner
- Bertozzi Carolyn R10% Owner
- Staben StevenChief Scientific Officer, 10% Owner
- Fischer LaurentDirector
based on 52.09M shares outstanding
US30d Avg
2.29M
60d Avg
2.29M
90d Avg
2.29M